Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 57Lymphoid 19CNS 16Genitourinary 15Gastrointestinal 15Sarcoma 14Other hematologic neoplasm 13Thoracic 9Dermatologic 8Myeloid 5Gynecologic 5Endocrine 4Classical hematology 4NET 2Head & Neck 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Head and Neck Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 315Radiotherapy 139Cetuximab 133pembrolizumab 131Docetaxel 122Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 29apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Thalidomide × Head & Neck × Clear all
NCT00026533 2017-06-06

Thalidomide in Treating Patients With Thyroid Cancer

University of Kentucky

Phase 2 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT00003850 2013-02-08

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡